Results 71 to 80 of about 24,516 (282)

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Eculizumab improves fatigue in refractory generalized myasthenia gravis [PDF]

, 2019
Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue ...
Andersen, Henning, De Bleecker, Jan, Howard, James F, Jr, Mantegazza, Renato, O'Brien, Fanny, Patra, Kaushik, REGAIN Study Group, the, Wang, Jing Jing   +7 more
core   +2 more sources

Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

Journal of the peripheral nervous system
Guillain‐Barré syndrome (GBS) is an acute, self‐limited, immune‐mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely affected patients.
Satoshi Kuwabara, Susumu Kusunoki, M. Kuwahara, Y. Yamano, Y. Nishida, Hirokazu Ishida, Tomoyuki Kasuya, Erik Kupperman, Qun Lin, G. Frick, S. Misawa   +10 more
semanticscholar   +1 more source

Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein, Haoqi Sun, Sophie Lehnerer, Lea Gerischer, Maximilian Mönch, Christian Meisel, Andreas Meisel, Pushpa Narayanaswami   +7 more
wiley   +1 more source

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

EClinicalMedicine, 2020
Background: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for ...
Djillali Annane, Nicholas Heming, Lamiae Grimaldi-Bensouda, Véronique Frémeaux-Bacchi, Marie Vigan, Anne-Laure Roux, Armance Marchal, Hugues Michelon, Martin Rottman, Pierre Moine   +9 more
doaj   +1 more source

Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data

BMC Nephrology
The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS).
Kristina Schönfelder, Lucas Kühne, L. Schulte-Kemna, J. Kaufeld, H. Rohn, Andreas Kribben, Bernd Schröppel, P. Brinkkötter, A. Gäckler   +8 more
semanticscholar   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report

Transplantation Reports, 2018
Background: Transplantation-associated thrombotic microangiopathy (TA-TMA) is relatively rare and may cause graft failure. Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the alternative complement pathway, resulting in TMA ...
Tomoko Kawanishi, Jumpei Hasegawa, Momoko Kono, Ayumi Ishiwatari, Toshie Ogawa, Yasutomo Abe, Mariko Endo, Hidetoshi Ishigooka, Masayoshi Okumi, Kazunari Tanabe, Sachiko Wakai, Hiroki Shirakawa   +11 more
doaj   +1 more source

Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Journal of Managed Care & Specialty Pharmacy
BACKGROUND Eculizumab and efgartigimod were approved to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (anti-AChR Ab-positive gMG).
Pei-Wen Lien, Mrinmayee Joshi, Jeffrey A. Tice, F. Agboola, D. Nikitin, Vinura Withanawasam, Saira Jatoi, Daniel R Touchette   +7 more
semanticscholar   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source